Taylor Hoffman Wealth Management boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 58.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,629 shares of the company’s stock after acquiring an additional 600 shares during the period. Taylor Hoffman Wealth Management’s holdings in Eli Lilly And Co were worth $187,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors also recently made changes to their positions in LLY. Ironwood Financial llc bought a new position in Eli Lilly And Co in the fourth quarter valued at about $30,000. Csenge Advisory Group bought a new position in Eli Lilly And Co in the third quarter valued at about $58,000. Cornerstone Advisors Inc. boosted its holdings in Eli Lilly And Co by 21.3% in the third quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock valued at $83,000 after acquiring an additional 136 shares during the last quarter. Atwood & Palmer Inc. boosted its holdings in Eli Lilly And Co by 267.0% in the fourth quarter. Atwood & Palmer Inc. now owns 734 shares of the company’s stock valued at $85,000 after acquiring an additional 534 shares during the last quarter. Finally, First Command Bank boosted its holdings in Eli Lilly And Co by 31.3% in the fourth quarter. First Command Bank now owns 834 shares of the company’s stock valued at $96,000 after acquiring an additional 199 shares during the last quarter. 80.84% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently issued reports on the company. Zacks Investment Research cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, December 18th. Citigroup cut Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 price target on the stock. in a report on Monday, November 26th. Morgan Stanley set a $116.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a report on Thursday, December 20th. BMO Capital Markets raised their price target on Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a report on Monday, December 24th. They noted that the move was a valuation call. Finally, Credit Suisse Group raised Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a research note on Wednesday, October 31st. Eleven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and an average target price of $111.41.
NYSE:LLY opened at $118.01 on Tuesday. Eli Lilly And Co has a 1-year low of $74.51 and a 1-year high of $121.84. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $125.67 billion, a price-to-earnings ratio of 21.26, a P/E/G ratio of 1.91 and a beta of 0.37.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. The company had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. During the same period in the previous year, the company posted $1.14 EPS. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. Research analysts anticipate that Eli Lilly And Co will post 5.6 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Friday, February 15th will be given a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.19%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 40.54%.
In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the firm’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Myles O’neill sold 25,000 shares of the firm’s stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $112.92, for a total value of $2,823,000.00. Following the sale, the senior vice president now directly owns 26,562 shares in the company, valued at approximately $2,999,381.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 817,843 shares of company stock worth $94,595,335. 0.11% of the stock is currently owned by insiders.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: Retained Earnings
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.